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Background. Analysis of genome-wide polymorphism in many organisms has potential to identify genes under
recent selection. However, data on historical allele frequency changes are rarely available for direct conﬁrmation.
Methods. We genotyped single nucleotide polymorphisms (SNPs) in 4 Plasmodium falciparum drug resistance
genes in 668 archived parasite-positive blood samples of a Gambian population between 1984 and 2008. This
covered a period before antimalarial resistance was detected locally, through subsequent failure of multiple drugs
until introduction of artemisinin combination therapy. We separately performed genome-wide sequence analysis of
52 clinical isolates from 2008 to prospect for loci under recent directional selection.
Results. Resistance alleles increased from very low frequencies, peaking in 2000 for chloroquine resistance-
associated crt and mdr1 genes and at the end of the survey period for dhfr and dhps genes respectively associated
with pyrimethamine and sulfadoxine resistance. Temporal changes ﬁt a model incorporating likely selection coefﬁ-
cients over the period. Three of the drug resistance loci were in the top 4 regions under strong selection implicated
by the genome-wide analysis.
Conclusions. Genome-wide polymorphism analysis of an endemic population sample robustly identiﬁes loci
with detailed documentation of recent selection, demonstrating power to prospectively detect emerging drug
resistance genes.
Keywords. resistance monitoring; population genetics; genomic surveillance; archival analysis; policy and practice.
An understanding of the adaptation of pathogens to
changing environments and speciﬁc control efforts is
important but challenging; however, developments in
genomic methods offer approaches that may become
widely effective. When new alleles are strongly selected
within a population, associated haplotypes in ﬂanking
regions of the genome affect local linkage disequilibrium
and the allele frequency spectrum [1]. However, evalua-
tion of such statistical signatures against evidence of
historical selection has rarely been performed directly,
as estimates obtained by measuring changes in allele
frequencies over time are rarely possible for natural
populations.
In the human malaria parasite Plasmodium falcipa-
rum, alleles have been widely surveyed for genes that
determine resistance to chloroquine (crt on chromo-
some 7 encoding the chloroquine resistance transporter
and mdr1 on chromosome 5 encoding a multidrug re-
sistance transporter) or antifolates (dhfr on chromo-
some 4 encoding the target of pyrimethamine and dhps
on chromosome 8 encoding the target of sulfadoxine).
Particular haplotypes at each of these chromosomal
loci have undergone selective sweeps [2–7], some of
these spreading from Asia into Africa [2, 8–10]. Several
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studies have compared proportions of alleles in endemic popula-
tions at different times, for example, in Mozambique over 5
years [11], Tanzania over 6 years [12], western Kenya over 8
years [13],Malawi over 8 years [14] and 9 years [15], Papua New
Guinea over 12 years [16], Gabon over 14 years [17], and eastern
Kenya over 14 years [18]. In each case, resistance alleles were
already common at the start of the survey period. In addition to
positive selection by drugs, there has also been a decline in prev-
alence of chloroquine resistance alleles after use of the drug
ended in particular populations [14, 19], highlighting the exis-
tence of ﬁtness costs and suggesting the potential for future rein-
troduction of chloroquine [20]. However, each of these temporal
comparisons covered only part of the period during which local
changes in drug resistance occurred, and none of them were di-
rectly related to attempts to detect or interpret signatures of se-
lection from genome-wide analyses.
Here, we report the longest temporal survey of drug resis-
tance genes within an endemic population, covering different
phases of antimalarial drug use and focusing on the 4 gene loci
in P. falciparum that are responsible for chloroquine resistance
(crt, mdr1) and antifolate resistance (dhfr, dhps). Parasite
samples were collected in The Gambia over a 25-year period
from 1984, when resistance was unknown locally, through the
subsequent gradual failure of chloroquine and antifolate
therapy, until the eventual switch to artemisinin combination
therapy in 2008. The changes in allele frequencies are related to
therapeutic policies and practices at different times during the
period. We then surveyed whole parasite genome sequences
from an independent sample of clinical isolates at the end of
this period and examined the statistical impact of selection on
these loci compared with the rest of the genome that encodes
more than 5000 other genes. Results highlight the accuracy of
genomic signatures of selection, as well as their transient
nature, and identify additional loci under recent strong selec-
tion, indicating the need to apply these approaches more inten-
sively in Africa where the public health implications of the
spread of drug resistance are most profound.
METHODS
Ethics Statement
The Joint Ethics Committee (JEC) of the Gambia Government
(JEC) and Medical Research Council Gambia Unit (MRC) ap-
proved this study. All subjects gave informed consent for sample
collection, and procedures were conducted in accordance with
the principles expressed in the Declaration of Helsinki.
Retrospective Sampling for P. falciparum Drug Resistance
Polymorphisms
Blood samples from subjects with P. falciparum malaria infec-
tions living in the Farafenni area of the North Bank Region of
The Gambia in West Africa were collected during 8 different
years from 1984 to 2008. Sample collection was part of previous
studies conducted by the MRC Gambia Unit that were ap-
proved by the JEC. Samples were stored in the MRC Gambia
laboratories as aliquots of heparinized blood frozen at −20°C or
as dried blood spots sealed with desiccant at ambient tempera-
ture. The identiﬁcation and extraction of stored samples for
this genotyping study were reviewed and approved by the JEC.
DNA extraction from each sample was performed using the
QIAamp DNA mini kit, and species-speciﬁc polymerase chain
reaction (PCR) was performed to identify samples with P. fal-
ciparum DNA. This screening identiﬁed 668 blood samples
with P. falciparum DNA available for genotypic analysis. The
samples came from individuals who had not received antima-
larial treatment during their infection prior to sampling: 132 in
1984, 102 in 1988, 66 in 1991, 87 in 1998, 97 in 2000, 70 in
2004, 78 in 2007, and 36 in 2008. The origins and summary
details of the sample sets are given in Table 1.
P. falciparum Drug Resistance Genotyping
The following 4 P. falciparum drug resistance loci were geno-
typed by restriction fragment length polymorphism analysis
of PCR products on ethidium bromide–stained agarose gels:
dhfr gene codons 51, 59, and 108 (chromosome 4, gene ID
Table 1. Sources and Summary Details of Blood Samples Collected Between 1984 and 2008 Used for Plasmodium falciparum
Genotyping
Year Time of Sampling Age Group
Type of Sampling and
Clinical Status
Previous Description
of Sampling
Number of
Samples Genotyped
1984 August All ages Community, asymptomatic [21] 132
1988 May 3–8 y Community, asymptomatic [22] 102
1991 June and November All ages Community, asymptomatic [23] 66
1998 September–December <15 y Health center, uncomplicated malaria [24] 87
2000 June–November All ages Community, asymptomatic Unpublished 97
2004 October–December <10 y Health center, uncomplicated malaria [25] 70
2007 November All ages Hospital, uncomplicated malaria [26] 78
2008 August–December <15 y Community, asymptomatic [27] 36
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PF3D7_0417200); mdr1 gene codon 86 (chromosome 5, gene
ID PF3D7_0523000); crt gene codon 76 (chromosome 7, gene
ID PF3D7_0709000); and dhps gene codons 437 and 540 (chro-
mosome 8, gene ID PF3D7_0810800). This was done using
previously described methods [28–30].
Analysis of Temporal Changes in Allele Frequencies
Proportions of isolates containing resistance alleles (either
alone or with sensitive alleles in the case of mixed genotype
infections) were compared between successive sample years,
and signiﬁcance was assessed using Fisher’s exact test. Then,
for selection modeling, allele frequencies in each year sampled
were estimated by counting 1 allele per isolate, randomly sam-
pling from mixed genotype isolates; 95% conﬁdence intervals
(CIs) were determined using the modiﬁed Wald method. We
made simpliﬁed assumptions of 2 parasite life cycles per year
and a resistance allele frequency of 0.01 in 1984. For chloro-
quine resistance, we modeled positive selection coefﬁcients of
Figure 1. Proportions of Plasmodium falciparum–infected individuals with each allele at 4 drug resistance loci in 8 surveys conducted in the Farafenni
area of The Gambia between 1984 and 2008. A, Chloroquine resistance loci (crt and mdr1). B, Antifolate resistance loci (dhfr and dhps). The numbers of
individual infections genotyped for each locus in each year are shown in brackets under each plot. Asterisk indicates signiﬁcant change (P < .05) in the
proportions of isolates with each allele between bracketed years (for dhfr, the proportion of samples with resistance type at each of the triple positions
dhfr-51I-59C-108N was compared between years). Abbreviation: WT, wild type.
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s = 0.15 for the crt-76T allele and s = 0.13 for the mdr1-86Y
allele until generation 39 (in 2003), followed by negative selec-
tion coefﬁcients of −0.10 and −0.15, respectively (representing
ﬁtness costs on these alleles in the absence of drug selection).
This was then compared with modeling constant positive selec-
tion coefﬁcients. For antifolate resistance, we modeled drug se-
lection coefﬁcients of s = 0.11 for the dhfr triple mutant (51I,
59R, 108N) allele and the dhps 437G allele throughout the
period.
P. falciparum Whole Genome Sequencing and Analysis
Sixty-nine isolates from the coastal area of The Gambia were
collected in 2008, processed, and subjected to paired-end short-
read sequencing using the Illumina HiSeq platform, following
methods previously described [31, 32]. Data from 65 of the iso-
lates were recently used in a genome-wide screen for evidence
of balancing selection [32]. The sequence read data from each
of these isolates are available from the European Nucleotide
Archive, with sample identiﬁers given in Supplementary
Table 1. Short-read sequence data were mapped to the
P. falciparum 3D7 reference genome (version 3, October 2012
release) using SMALT (http://www.sanger.ac.uk/resources/
software/smalt/) run with default parameters. Putative single
nucleotide polymorphisms (SNPs) were identiﬁed with SAM-
tools [33] (parameters: samtools mpileup –Q 23 –d 2000 –C50
–ugf) and ﬁltered using the vcfutils.pl script (parameters: var-
Filter –d 10 –D 2000). Calls were made at each position that
passed initial ﬁltering using a majority rules approach, whereby
the allele supported by the greatest read count was selected.
Positions covered by fewer than 5 reads were marked as
missing data for that isolate. SNPs were also ﬁltered in order to
remove those located in subtelomeric regions and the hypervar-
iable var, riﬁn, and stevor gene families. Following this ﬁltering,
17 of the isolates each had >5000 points of missing SNP data
(out of 86 717 identiﬁed SNPs). These were dropped from
subsequent analysis in order to focus on the majority of isolates
(n = 52), which had higher coverage. Individual SNPs were dis-
carded if >3 of these isolates had missing data, and the small
amount of remaining missing data were imputed with PHASE
2.1 [34].
Figure 2. Models of selection at 4 Plasmodium falciparum drug resistance loci related to allele frequency changes between 1984 and 2008. Allele fre-
quencies (with 95% conﬁdence intervals) of the resistance alleles of (A) chloroquine resistance genes crt and mdr1 and (B) antifolate resistance genes dhfr
and dhfr are plotted on a time scale, assuming 2 parasite life-cycle generations per year (50 generations from 1984 to 2008). The timing and relative
strength of selection at each of the 4 loci was modeled with the following parameters: (A) Chloroquine resistance loci: for crt 76T positive drug selection
coefﬁcient s = 0.15 until generation 39 (in 2003) and s =−0.1 thereafter; for mdr1 86Y positive selection s = 0.13 until generation 39 and s =−0.15 thereaf-
ter. B, Pyrimethamine and sulfadoxine antifolate resistance loci: for dhfr triple mutant allele positive selection s = 0.11, and for dhps 437G positive selec-
tion s = 0.11, throughout the period.
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Detection of Signatures of Positive Directional Selection
The standardized integrated haplotype score |iHS| was calculat-
ed for each SNP with a minor allele frequency of >0.05 as previ-
ously described [35]. This analysis makes an assumption that
the majority allele at each SNP position within an isolate com-
prises a parasite haplotype. The genetic map distance between
markers inferred with LDhat 2.2 [36] was measured using a
block penalty of 5, 10 million rjMCMC iterations, and a burn-
in of 100 000 iterations. Regions under selection were identiﬁed
by calculating the distance required for the extended haplotype
homozygosity (EHH) of high-scoring SNPs (standardized |iHS|
>3) to decay to 0.05, with overlapping regions combined into a
single window of selection. EHH scores were calculated using
the SWEEP program [37].
RESULTS
Survey of Drug Resistance Genotypes Over a 25-Year Period
First, we investigated the historical impact of antimalarial drug
pressure in The Gambia by surveying drug resistance polymor-
phisms in 4 P. falciparum genes in samples from 8 time points
between 1984 and 2008, with genotyping performed on 668 in-
dividuals (Figure 1 and Supplementary Table 2). In the ﬁrst
year, no resistance alleles were detected at 2 of the loci (pfcrt and
pfdhps), while resistance alleles at the other 2 loci (pfmdr1 and
pfdhfr) were observed in only very few isolates. Over subsequent
survey time points, proportions of isolates with resistance alleles
increased progressively and highly signiﬁcantly (P < 10−7 for
each locus), with the prevalence of chloroquine resistance alleles
reaching a peak in 2000 (76% for the crt 76T allele, 78% for the
mdr1 86Y allele). There was a highly signiﬁcant decline in preva-
lence of the mdr1 86Y allele after 2000 through the end of the
survey period (P < 10−7; Figure 1). Proportions of isolates with
antifolate resistance alleles peaked later (94% for dhfr alleles in
2007, 86% for the dhps 437G allele in 2008; the dhps resistance
allele 540E that exists in many parts of Africa was not present in
any of 623 isolates typed for the causal SNP).
Direct Evidence of Selection on Drug Resistance Loci
For analysis of population genetic processes, allele frequencies
are considered rather than the prevalence of infections with a
given allele, as the latter is inﬂuenced by the existence of multiple
genotypes in some isolates (and would vary over time for any
parasite polymorphism when variation in endemicity inﬂuences
rates of superinfection). Therefore, to estimate allele frequencies,
we counted 1 allele at each locus per isolate, randomly sampling
in the case of isolates that had mixed genotypes, and estimated
the 95% CIs based on numbers of isolates sampled. Figure 2
shows that changes in allele frequencies occurred at different
times and rates during the study period. To explore the intensity
of selection over time, we compared these data to frequencies
generated with a simple model, applying reasonable assumptions
Figure 3. Genome-wide signatures of positive directional selection derived from sequences of a population sample of 52 Plasmodium falciparum clini-
cal isolates collected in The Gambia in 2008. The standardized integrated haplotype score (|iHS|) is calculated from single nucleotide polymorphism (SNP)
data using all SNPs with an allele frequency of >0.05 (in at least 3 individuals). SNPs on individual chromosomes are identiﬁed by alternating black/red col-
oring, with high-scoring SNPs (standardized |iHS| > 3) highlighted in blue. Vertical black lines indicate the position of the 4 drug resistance loci that had
been surveyed in the retrospective analysis in this study. Genes within each of the regions of elevated |iHS| supported by at least 2 SNPs are listed in
Table 2.
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of assumed ﬁtness costs and positive selection coefﬁcients that
reﬂect historical therapeutic use. Given that an annual transmis-
sion window occurs primarily between August and November,
we assumed an average of 2 parasite life-cycle generations per
year (Figure 2). The crt and mdr1 chloroquine resistance allele
frequencies ﬁt a model in which positive selection continued to
operate until sometime between 2000 and 2004 (the model
shown sets this as 2003 assuming 2 generations per year;
Figure 2A). After this time point, assumed ﬁtness costs modeled
an allele frequency decline, which was more apparent for mdr1
than crt. The frequency changes at these chloroquine resistance
loci clearly did not ﬁt a model of constant positive selection
(Supplementary Figure 1). In contrast, changes in frequencies of
dhfr and dhps antifolate resistance alleles closely reﬂected expec-
tations under continuous positive selection throughout the period
studied (Figure 2B).
Signatures of Selection in the Context of Genome-Wide
Analysis
In order to investigate genome-wide signatures of selection, we
sampled 69 P. falciparum clinical isolates from The Gambia in
2008, and analyzed polymorphism throughout the parasite
genome by paired-end short-read sequencing. We identiﬁed
86 717 biallelic SNPs in a set of 52 isolates with the most com-
plete data (17 isolates with >5000 untyped SNPs were exclud-
ed). Of these, 28 284 SNPs had a minor allele frequency of
>0.05, which was informative for long-range haplotype analysis
to assess the impact of selection. Calculation of the |iHS| iden-
tiﬁed 22 discrete genomic regions containing a candidate
signature of selection, as deﬁned by 2 or more SNPs with stan-
dardized |iHS| >3 (Figure 3 and Table 2). Three of the top 4 sig-
natures, as deﬁned by the number of supporting SNPs with
high |iHS| values, contained the dhfr, crt, and dhps drug resis-
tance genes (Figure 3). We did not detect any comparable sig-
nature around the mdr1 gene (locus Pf3D7_0523000), although
EHH was associated with the mdr1 86Y resistance allele
(Figure 4), which had declined in frequency by 2008. In associ-
ation with this resistance allele, it took a distance of 143.8 kb
for EHH to decay to a level of 0.05, as opposed to 19.4 kb for
the wild-type sensitive allele. For the other drug resistance
genes, long haplotypes were associated with resistance alleles
present at high frequency in 2008 (Figure 4), as expected for
Table 2. Genomic Windows Containing Signatures of Recent Positive Selection as Identiﬁed by Genome Wide Standardized Integrated
Haplotype Score Scan
Chromosome
Start
Position (kb)
End
Position (kb)
Region
Size (kb)
Number of
Supporting Single
Nucleotide
Polymorphisms
Number of
Genes in the
Region GenesWithin Region
1 94.7 338.3 243.6 4 63 PF3D7_0102100 – PF3D7_0108300
2 763.8 829.9 66.1 3 20 PF3D7_0218700 – PF3D7_0220600
3 120.4 249.7 129.3 4 30 PF3D7_0302200 – PF3D7_0305100
4 274.5 289.6 15.1 2 3 PF3D7_0405100 – PF3D7_0405300
4 585.1 766.1 181.0 14 46 PF3D7_0413000 – PF3D7_0417400
4 966.5 993.0 26.5 3 6 PF3D7_0421200 – PF3D7_0421700
5 1129.4 1323.6 194.2 11 58 PF3D7_0527100 – PF3D7_0532700
6 340.7 528.5 187.8 4 49 PF3D7_0608100 – PF3D7_0612800
6 1031.1 1301.9 270.8 65 59 PF3D7_0625300 – PF3D7_0631100
7 240.8 520.0 279.2 53 70 PF3D7_0704800 – PF3D7_0711700
7 589.6 696.4 106.8 4 30 PF3D7_0712900 – PF3D7_0715800
7 1253.1 1351.5 98.4 4 21 PF3D7_0729400 – PF3D7_0731300
7 1380.5 1406.7 26.2 4 8 PF3D7_0731800 – PF3D7_0732500
7 1427.6 1437.7 10.1 4 0 . . .
8 427.6 708.9 281.3 18 66 PF3D7_0808500 – PF3D7_0814900
8 974.3 1193.0 218.7 12 59 PF3D7_0821800 – PF3D7_0827600
9 144.6 371.7 227.1 8 51 PF3D7_0903300 – PF3D7_0908000
11 518.9 775.4 256.5 3 77 PF3D7_1113300 – PF3D7_1120600
11 1197.7 1477.5 279.8 10 70 PF3D7_1131100 – PF3D7_1137600
12 57.0 178.6 121.6 2 29 PF3D7_1200700 – PF3D7_1203400
12 1709.0 1745.0 36.0 6 6 PF3D7_1240400 – PF3D7_1240900
14 3050.6 3203.2 152.6 10 34 PF3D7_1474400 – PF3D7_1477700
Regions on chromosomes 4, 7, and 8, which encompass the drug resistance genes dhfr (Pf3D7_0417200), crt (Pf3D7_0709000), and dhps (Pf3D7_0810800),
respectively, are in bold italics.
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loci under very recent positive selection and contributing to the
strong |iHS| signatures at these loci.
The scan shown in Figure 3 clearly identiﬁes other genomic
loci under recent positive selection (Table 2). An exceptionally
strong signature, supported by 65 SNPs with standardized
|iHS| > 3, implicates a large region of approximately 271 kb on
chromosome 6, which covers 59 genes. Strong directional selec-
tion on the region has been previously inferred by analysis of
genome-wide sequence data from a population in Senegal [38]
and SNP microarray data from a combined population sample
from The Gambia and Senegal [39]. The identiﬁcation of a
strong |iHS| signature in the region of chromosome 11 contain-
ing the ama1 antigen gene (locus Pf3D7_1133400) is also
notable, as this gene has been previously implicated to be under
balancing selection [32] and positive directional selection [39].
DISCUSSION
We have described allele frequency trajectories over time in re-
lation to known selective causes and then evaluated signatures
of directional selection in a genome-wide analysis. The tempo-
ral changes in P. falciparum drug resistance allele frequencies
over the 25-year period were consistent with the history of
varying antimalarial drug use in the Gambian population
during this period. Resistance-associated alleles were virtually
absent from the earliest survey in 1984, as expected from results
of a large survey in this area in 1982 that indicated no resistance
of P. falciparum to chloroquine, pyrimethamine, or dapsone
(sulfadoxine was not used in the country at that time) [40].
Chloroquine was the ﬁrst-line therapy during this period, so re-
sistance to this drug emerged ﬁrst [41, 42], and we show pro-
gressive increases in allele frequencies of crt-76T and mdr1-86Y
in all subsequent surveys until 2000. Although sulfadoxine–
pyrimethamine remained ofﬁcially as second-line treatment
until 2004, its use for ﬁrst-line treatment is considered to have
been widespread for a long time before this, given the apparent
failure of chloroquine [43]; the continuous rise in frequency of
antifolate drug resistance alleles dhfr-51I-59C-108N and dhps-
437G reﬂects this.
The temporal allele frequency change data at each of these 4
loci closely ﬁt with expectations from a very simple selective
model that had only a few parameters, incorporating constant
ﬁtness costs. We excluded other complexities, such as seasonal
differences in selection [44], differences in ﬁtness costs, times
Figure 4. Extended haplotype homozygosity (EHH) decay around each of the 4 drug resistance genes in the sequenced population sample from 2008.
Blue indicates EHH decay of the major allele (with allele frequency >0.5 in 2008), red indicates EHH decay of the minor allele. Causative resistance poly-
morphisms in dhfr and crt were not called in the single nucleotide polymorphism (SNP) typing applied to the whole genome sequence data. Consequently,
these EHH decay plots are presented for the nearest called SNP. A, EHH decay centered on mdr1 codon 86. The resistance allele was present at a frequen-
cy of 0.27 and it required 143.8 kb for EHH to decay to a level of 0.05, as opposed to 19.4 kb for the wild-type sensitive allele. B, EHH decay for chromo-
some 4 SNP at position 750 221, the nearest typed SNP to dhfr (separated by <2 kb). The major allele was present at a frequency of 0.87 and required
59.4 kb for EHH to decay to 0.05, while the minor allele decayed to this level in 40.0 kb. C, EHH decay for chromosome 7 SNP at position 7 399 258, the
nearest typed SNP to crt codon 76 (separated by 4.4 kb). The major allele was present at a frequency of 0.94 and required 82.3 kb for EHH to decay to
0.05, while the minor allele decayed to this level in 15.9 kb. D, EHH decay to 0.05 centered on dhps codon 437. The major allele was present at a frequency
of 0.77 and required 84.9 kb for EHH to decay to 0.05, while the minor allele decayed to this level in 31.1 kb.
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of introduction of different alleles, and possible epistatic inter-
actions among alleles at different loci [29], which could con-
tribute to a more detailed model if the relevant parameters were
known [45]. Estimated selection coefﬁcients depend on the
number of parasite life-cycle generations per year. Our esti-
mates, which are based on either 2 or 3 generations per year,
are similar to those from studies elsewhere in Africa [15, 18],
except where an exceptionally large number of generations per
year was assumed [13]. The timing of the changes in selection
are consistent with perceptions that the actual use of chloro-
quine declined markedly in response to widely perceived thera-
peutic failure,while sulfadoxine–pyrimethamine continued tobe
used although chloroquine alone was recommended as ﬁrst-line
treatment until 2004 and in combination with sulfadoxine–
pyrimethamine until 2008.
In the genome-wide analysis of samples from 2008, 3 of
these drug resistance loci (crt, dhfr, and dhps) were within the
top 4 |iHS| signatures, independently indicating recent strong
positive selection. There was power to detect these signatures
by sampling at that single time point, as the resistance-associated
alleles remained common in the population until the popula-
tion sample was taken for genome-wide sequencing in 2008,
even though the frequency of the crt resistance allele may have
begun to decline by that time. In contrast, the fact that the
mdr1 gene region was not identiﬁed from the genome-wide
scan is likely to be due to a lower resistance allele frequency,
which had declined very signiﬁcantly between 2000 and 2008.
Although the mdr1 haplotype homozygosity was greater for the
resistant allele than for the sensitive allele, it was not signiﬁ-
cantly greater than the possible range expected under neutrali-
ty, given the relatively low allele frequency, and thus a transient
genomic signature might have been missed by sampling too
late. Two other studies from this area of West Africa have also
not detected clear signals of selection at this locus by |iHS| anal-
ysis [38, 39]. One of these involved analysis on Senegalese
samples taken during a period of chloroquine and amodiaquine
use in that country [38]. However, a separate analysis of a sub-
sample of the Senegalese population sample did show a selec-
tive sweep signature at the mdr1 locus [46], supporting the idea
that exact location or timing of sampling may have a major
effect in this situation. We cannot exclude the possibility that
there has been selection on multiple preexisting alleles of mdr1,
as was the case in a soft selective sweep on alleles containing
copy number ampliﬁcations of the mdr1 gene in Southeast
Asia [3], although copy number variants at this locus are ex-
tremely rare in West Africa [47].
Of the other genomic loci identiﬁed as most likely to have
been under recent directional selection, a few were also identiﬁed
recently from independent analysis of samples from The
Gambia and Senegal using an Affymetrix custom SNP array [39]
and sequence-based analysis of parasites from Senegal [38]. The
selective signature on chromosome 6 was previously associated
with parasites that were pyrimethamine resistant in Senegal [38],
but the test could not identify the exact gene under selection.
Two of the genes within the locus (PF3D7_062800 and
PF3D7_0630700) have proposed roles in folate metabolism
pathways, so it could be speculated that selection operates on
compensatory mutant alleles that offset loss of dihydrofolate re-
ductase function from partial inhibition by subtherapeutic levels
of pyrimethamine. However, due to the wide selection window
and limitations of haplotype-based methods, we cannot exclude
the possibility that other genes within the locus are the targets of
selection. We consider it likely that a strong signature in chromo-
some 11 may be due to recent immune selection of a novel allele
of ama1 added to a broad repertoire of alleles under balancing
selection [39]. The causes of selection in these cases deserve de-
tailed investigation, as there are only a few loci genome wide that
show such strong local selective sweeps. The likelihood that we
have already detected most of the genomic loci affected by such
strong recent selection has 2 main implications. First, if future
drug resistance alleles are under similarly strong selection, in
most cases, it should be possible to detect the emerging selective
sweeps in genome-wide scans, and efforts toward such surveil-
lance should be increased in Africa where the burden of malaria
remains highest and the public health signiﬁcance of drug resis-
tance is greatest. Second, other tests are needed to detect more
moderate or complex processes of positive selection that domi-
nate in evolution generally and that will pertain to important
phenotypes other than drug resistance.
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